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Abstract
Chronic exposure to inorganic arsenic (iAs) found in the environment is one of the most significant and widespread
environmental health risks in the U.S. and throughout the world. It is associated with a broad range of health effects from
cancer to diabetes as well as reproductive and developmental anomalies. This diversity of diseases can also result from
disruption of metabolic and other cellular processes regulated by steroid hormone receptors via aberrant transcriptional
regulation. Significantly, exposure to iAs inhibits steroid hormone-mediated gene activation. iAs exposure is associated with
disease, but is also used therapeutically to treat specific cancers complicating an understanding of iAs action.
Transcriptional activation by steroid hormone receptors is accompanied by changes in histone and non-histone protein
post-translational modification (PTM) that result from the enzymatic activity of coactivator and corepressor proteins such as
GRIP1 and CARM1. This study addresses how iAs represses steroid receptor-regulated gene transcription. PTMs on histones
H3 and H4 at the glucocorticoid receptor (GR)-activated mouse mammary tumor virus (MMTV) promoter were identified by
chromatin immunoprecipitation analysis following exposure to steroid hormone6iAs. Histone H3K18 and H3R17 amino acid
residues had significantly different patterns of PTMs after treatment with iAs. Promoter interaction of the coactivator CARM1
was disrupted, but the interaction of GRIP1, a p160 coactivator through which CARM1 interacts with a promoter, was intact.
Over-expression of CARM1 was able to fully restore and GRIP1 partially restored iAs-repressed transcription indicating that
these coactivators are functionally associated with iAs-mediated transcriptional repression. Both are essential for robust
transcription at steroid hormone regulated genes and both are associated with disease when inappropriately expressed. We
postulate that iAs effects on CARM1 and GRIP1 may underlie some of its therapeutic effects and as well be associated with
its toxic effects.
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Introduction
Chronic exposure to inorganic arsenic (iAs), in the most
prevalent form of arsenite (As
3+) from drinking water is one of
the most significant and widespread environmental health risks in
the U.S. and throughout the world [1]. Epidemiologic evidence
links iAs exposure to an increased risk of lung, bladder, skin and
other cancers, type 2 diabetes, vascular and cardiovascular disease,
and reproductive and developmental anomalies [2], all of which
can be linked to inappropriate steroid or nuclear receptor-
mediated gene regulation which can have deleterious effects on
every metabolic system and is associated with many forms of
cancer [3–6].
Micromolar amounts of iAs inhibit transcription mediated by
the glucocorticoid receptor (GR), the progesterone receptor (PR),
the androgen receptor (AR), the estrogen receptor (ER) and the
mineralocorticoid receptor (MR) [7–9], as well as the thyroid
hormone (TR) and the retinoic acid (RAR) receptors [10]. This
suggests an iAs target common to all or many nuclear receptor-
regulated gene promoters but a mechanism has yet to be
identified. Steroid hormone-regulated receptors belong to the
superfamily of nuclear receptors that includes the GR, PR, ER,
MR, and AR. All use similar transcriptional activation mecha-
nisms to regulate physiological responses to a broad range of
internal and external stimuli [11].
Following ligand binding, transcription by steroid receptors is
initiated by receptor-DNA binding and changes in chromatin
structure contributed to by changes in histone post-translational
modifications (PTMs) [12]. Arsenic-associated changes in histone
PTMs have been identified in transcriptional activation from some
non-steroid regulated promoters [13] and global changes have
been reported in response to iAs at histone H3 [14]. Histone
PTMs, are regulated by coactivator or corepressor proteins [15]
that interact with promoters via protein-protein interactions with
the steroid receptor itself, or with other promoter-associated
proteins. These co-regulatory proteins act as transducers between
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targets for PTMs mediated by cell signaling pathways [16].
Coactivators such as CARM1 (coactivator-associated arginine
methylatransferase) have enzymatic activities on histones and non-
histone, promoter-associated proteins [17,18]. CARM1 targets
histone H3R17 and H3R26 for methylation upon activation of
both ER and GR-regulated promoters [19,20] and associates with
these promoters by binding to one of the three p160 coactivators
(SRC1, SRC2/GRIP1/TIF2, or SRC3/pCIP/AIB1/ACTR/
RAC3) [20,21] which in turn bind directly to the DNA-bound
steroid receptor.
To understand how iAs represses steroid hormone-mediated
gene transcription we sought to determine when in the
transcription process an iAs effect could be detected and whether
histone modification patterns changed in response to hormone
alone compared to hormone plus iAs at the MMTV promoter. We
found that iAs represses GR-mediated chromatin remodeling and
transcription initiation and that methylation and acetylation at
histone H3R17 and H3K18 respectively, decreased within
minutes of iAs addition. Both of these histone PTMs are associated
with transcriptional activation at steroid hormone-regulated
promoters. Additionally, it was determined that CARM1 was
absent from the promoter after treatment with iAs. Unexpectedly,
while CARM1 may be a target for iAs, GRIP1 is also a probable
target even though unlike CARM1 it was still associated with the
promoter when cells were treated with iAs. Finally, the data
suggest iAs-inhibited transcription is mediated through an indirect
effect on one or both of these coactivator proteins that may be via
deregulation of a cell signaling pathway.
Results
iAs Inhibits transcription from the GR-regulated MMTV
Promoter
To determine whether iAs inhibits GR-mediated transcription
from a stably integrated MMTV-chloramphenicol acetyltransfer-
ase (MMTV-CAT) reporter gene, 1470.2 cells were treated with
100 nM Dex6iAs at a range of concentrations that can be found
in drinking water. In contrast to a transiently expressed reporter
gene, stably integrated MMTV-CAT is associated with histone
proteins in a regularly spaced chromatin conformation [22] and
resembles that of an endogenous gene (Fig. 1A). CAT activity was
inhibited 20–50% with Dex plus 0.5 mMt o8mM iAs compared to
cells treated with Dex alone (Fig. 1B).
To determine whether iAs inhibited transcription at initiation or
elongation cells were treated with 5 nM Dex68 mM iAs and the
amount of initiated CAT transcript from the MMTV promoter
was determined by nuclear run-on analysis. Treatment with 5 nM
Dex was used to slow the transcription process to enable
evaluation of early events in activation. Dex alone increased
transcript initiation with the peak at about 120 min and decreased
initiation by 180 min, indicative of transcriptional repression
(Fig. 1C). In contrast, treatment with Dex +8 mM iAs inhibited
initiation of CAT mRNA. These data suggested that iAs inhibits
transcription initiation. To test this further, restriction enzyme
accessibility assays (REAAs) were done to determine whether iAs
affects chromatin remodeling, an event associated with initiation.
A Sac1 endonuclease cleavage site in the NucB region of the
MMTV-CAT promoter is accessible after treatment with Dex but
is less accessible before treatment and is an indicator of a GR-
induced structural transition in the chromatin [23]. Treatment of
cells with 5 nM Dex +8 mM iAs versus 5 nM Dex alone inhibits
access to the Sac1 cleavage site by 30 minutes and by 60 minutes
chromatin access decreases to less than or equal to basal levels
(Fig. 1D). This suggests that the MMTV promoter shuts down
progressively with time, in agreement with the nuclear run-on
experiments where transcript is still associated with the promoter
at 60 minutes but is not by 120 minutes when iAs is present. We
do not view the seeming discrepancy in promoter accessibility and
the presence of initiated transcripts at 60 minutes a problem
because transcripts detected at 60 minutes would have initiated
before the chromatin template was shut down and thus there
should be a lag in when promoter access is inhibited and when
transcript can be detected. Thus iAs inhibits transcription
initiation and associated chromatin remodeling at the GR-
regulated MMTV promoter.
Accumulated CAT mRNA was measured by qRT-PCR and by
2 hours there was significantly more CAT mRNA with Dex alone
than with Dex plus 8 mM iAs (Fig. 1E), in agreement with the
pattern of transcript initiation observed (Fig. 1C). Transcription at
the endogenous GR-regulated serum glucocorticoid kinase (SGK)
promoter was also inhibited by iAs (Fig. 1F) which indicates that
the inhibitory effect of iAs on the stably integrated MMTV
promoter recapitulates events on an endogenous promoter.
Treatment with 8 mM iAs alone showed no change in the amount
of CAT or SGK transcripts from background levels (Fig. 1E & F).
Together, these data raised the possibilities that iAs may inhibit
GR binding or stability at the glucocorticoid response element
(GRE), or alternatively, the binding of another promoter-
associated protein essential for initiation and activation.
GR binds to promoter DNA in the presence of iAs
GRs are predominantly cytoplasmic prior to ligand binding and
translocate to the nucleus and to targeted GREs when ligand is
bound to the receptor [24]. It was previously shown that low levels
of iAs do not significantly alter GR translocation into the nucleus,
but whether iAs affects GR binding to the GRE was not tested [7].
To determine if iAs affects GR/GRE binding, 1470.2 cells were
treated with 5 nM Dex68 mM iAs for 15, 30, 60, 120, or
180 min. Chromatin immunoprecipitation (ChIP) analysis was
done to determine GR association with the MMTV promoter on
nucleosome B (NucB) that has 4 GREs. GR was associated with
NucB by 15–30 min of treatment with no detectable difference in
cells treated with Dex6iAs (Fig. 2A). These data confirm that GR
translocates to the nucleus, and binds to the MMTV GRE in the
presence of iAs.
To determine whether iAs affects the DNA-binding kinetics of
ligand-bound GR, electromobility shift assay (EMSA) competitions
were done. Nuclear extracts (NEs) made from cells treated for
30 min with 50 nM Dex alone or 50 nM Dex plus 8 mM iAs were
incubated with a radiolabeled consensus GRE [25] with 0, 5x,
15x, or 30x molar excess of unlabeled competitor GRE. 50 nM
versus 5 nM Dex was used in this assay to allow detection of GR
bound to the GRE. With 5 nM Dex fewer GRs enter the nucleus
and bind to the GRE than with 50 nM resulting in a weak shifted
signal. GR was competed from the radiolabeled GRE with as little
as 5x unlabeled competitor GRE and almost fully with 15–30x
(Fig. 2B). The slope, based on values from quantification of the
shifted bands, was almost identical with either treatment (see
Inset). These data indicate that treatment with Dex6iAs does not
significantly change the DNA binding characteristics of GR under
conditions in which transcriptional activation is inhibited by iAs,
and therefore DNA binding is an unlikely explanation for iAs-
associated transcriptional repression from the MMTV promoter.
Effects of iAs on GR-mediated Histone Modification
Activation and repression of transcription is accompanied by
changes in histone PTMs and such modifications occur at the
Arsenic Inhibits CARM1
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6766Figure1.iAs inhibitstranscriptionfromtheMMTVandSGKpromoters.(A)MMTVpromoterwithNucsA–C. Largearrowindicates transcription
start site and small arrows, PCR primers in NucB. (B) CAT activity in 1470.2 cells treated (4 h) with 100 nM Dex6iAs. CAT activity expressed as a ratio
relative to cells treated with 100 nM Dex alone (arbitrarily set at 1). n=3replicates in a representative experiment. (C) Nuclear run-on analysis from the
MMTVpromoterincellstreatedwith5 nMDex68 mM iAs fortimesindicated.Foldchange=(CATmRNAhybridized-background(pUC))/5sRNA) relative
to basal transcription (no treatment) arbitrarily set to one. n=3 replicates from two independent experiments. (D) REAA with restriction enzyme Sac1.
SacI-digested DNA from cells treated for 30 or 60 min with 5 nM Dex68 mM iAs indicates an ‘‘open’’ or ‘‘closed’’ chromatin template at MMTV NucB
measured by qPCR with primers that span the SacI site in NucB. The zero value represents basal SacI digestion to which all treated values were
compared. n=3independent experiments. **P-value,0.01. (E & F) CAT or SGK mRNA measured by qRT-PCR. Cells treated with 5 nMDex68 mM iAs for
times indicated. Both (E&F) are data from the same experiment done in triplicate that is representative of 2 independent experiments.
doi:10.1371/journal.pone.0006766.g001
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Differences in histone PTMs in cells treated with Dex6iAs could
indicate an iAs effect on the histone itself or on a protein with
histone modifying activity, such as a coactivator or corepressor.
ChIP assays were done with antibodies to specific acetylated or
methylated amino acid residues and changes in modification at
NucB on the MMTV promoter were determined. Because histone
PTMs occur temporally, as has been demonstrated on the GR and
PR-regulated MMTV promoter [26,28] and on the estrogen
receptor-regulated pS2 promoter [29] all experiments were done
in a time course as in Fig. 1E.
Following treatment with 5 nM Dex68 mM iAs there were no
significant differences between treatments in acetylation at histone
H4, at amino acids H4K5, H4K8, or H4K12 or on histone H3 at
H3K14 and H3K4 (data not shown). These amino acids were
targeted because they have been shown by others to undergo PTM
changes upon activation of transcription. Histone H3K18
acetylation (H3K18ac) occurs with H3R17 methylation
(H3R17me) on the estrogen-regulated pS2 promoter [19] and
H3R17 is methylated at the MMTV promoter in response to GR
activation [20]. We found that H3K18ac was inhibited by
treatment with Dex+ iAs by 15 to 30 min (Fig. 3A). The increase
in H3K18ac in response to Dex alone was just slightly higher than
basal levels. In contrast, cells treated with Dex + iAs showed no
increase in acetylation at 15 or 30 min. but instead a significant
decrease relative to basal levels and importantly, relative to levels
seen with Dex alone. At the estrogen-responsive pS2 promoter,
H3K18ac increases early in activation and decreases significantly
with time and transcriptional repression [19] similar to what is
shown here at the GR-responsive MMTV promoter. Thus,
H3K18ac associated with steroid hormone-mediated transcrip-
tion, is disrupted by iAs. Acetylation differences did not occur
globally but were promoter-specific, an important distinction
because iAs does not inhibit transcription from all promoters.
Additionally, the decrease in H3K18ac was not due to histone H3
loss (Fig. 3B).
To determine whether H3R17me correlates with H3K18ac in
response to activation by GR, cells were treated with 5 nM
Dex68 mM iAs. H3R17me increased by 15 min of treatment with
Dex alone, but not in the presence of iAs (Fig. 3C). Together, the
decrease in H3K18ac and H3R17me in cells treated with Dex +
iAs versus Dex alone suggests that iAs-mediated inhibition of
transcription may, at least in part, be due to changes in histone
modification.
CBP/p300 at the MMTV Promoter
Both CBP and p300 are protein acetyltransferases that interact
with the MMTV promoter [28,30] and can acetylate H3K18 in
association with transcriptional activation at steroid hormone
regulated promoters [19,27]. Because H3K18 is less acetylated in
the presence of iAs than in cells treated with Dex alone, these
proteins became candidate iAs targets. Both proteins are post-
translationally modified by cell signaling pathways and the PTMs
can affect their enzymatic activity or their interaction with the the
promoter via p160 coactivators, SRC1, GRIP1/SRC2, or AIB1/
SRC3 [31,32]. To determine whether iAs inhibits CBP interaction
with the MMTV promoter at NucB, ChIP assays were done after
cells were treated with 5nM Dex68 mM iAs (Fig. 4A). No
treatment-specific differences were found in promoter association
by CBP. ChIP experiments were also done with antibody to p300
with a similar result (data not shown).
To determine whether over-expression of CBP could restore
transcription in cells treated with Dex+iAs, cells were transfected
with an expression plasmid for CBP and after recovery were
Figure 2. GR binds to the MMTV promoter equally in the
presence of Dex6iAs. (A) ChIP analysis of GR interaction with NucB.
Cells were treated with 5 nMDex68 mM iAs and ChIP assays were done
with antibody to GR. NucB bound by GR was quantified by qPCR or by
conventional PCR. n=7–8independent experiments. (B) EMSAs done with
NEsfrom1470.2 cells that were untreated (lane 2–0) or treated with50 nM
Dex68 mMi A sf o r3 0m i n u t e s .[
32P]-labeled consensus GRE65, 15, and 30-
fold molar excess unlabeled competitor GRE visualized as shifted band by
PhosphorImager analysis. The Inset graph shows the competition
quantified (shifted probe/(Free+shifted)) from each reaction shown.
doi:10.1371/journal.pone.0006766.g002
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CBP was unable to restore transcription in iAs-treated cells when
compared to transcription seen with Dex alone (Fig. 4B). Thus,
although H3K18 is not acetylated with iAs treatment there was no
apparent difference in the presence of CBP at NucB and over-
expression did not restore transcription. Over-expression of p300
was also unable to restore iAs-mediated transcriptional repression
(data not shown). Together these data suggest that iAs may
inactivate the enzymatic activity of either CBP, p300 or both
Figure 3. iAs inhibits histone H3K18 acetylation and H3R17
methylation. (A) 1470.2 cells were treated with 5nM Dex68 mM iAs for
the indicated times and ChIP assays were done with an antibody to
H3K18ac. H3K18ac at NucB represents qPCR values from primers/probe
to NucB corrected for Input DNA, expressed as a ratio of treated to
untreated cells (0) arbitrarily set to 1. n=4–5 independent experiments.
(B) Western blot analysis of NEs from cells treated as above with
antibody to H3K18ac and b-actin. (C) 1470.2 cells treated with 5 nM
Dex68 mM iAs as above and ChIP assays were done with an antibody to
H3R17me. qPCR was done with primers/probe to NucB and analyzed as
above. n=3–5 independent experiments.
doi:10.1371/journal.pone.0006766.g003
Figure 4. CBP binds to the MMTV promoter in the presence of
iAs but does not restore iAs-repressed transcription. (A) ChIP
assay in 1470.2 cells with an antibody to CBP. Treatment was with 5 nM
Dex68 mM iAs for the times indicated. qPCR was done with primers to
NucB and values were corrected for Input DNA and expressed as a ratio
of treated to untreated (0) arbitrarily set to 1. n=9 independent
experiments. (B) Cells were transfected with pcDNA3-CBP-Flag or Empty
vector at indicated concentrations and treated with 5 nM Dex68 mM
iAs for 24 h. Zero is untreated baseline activity. CAT mRNA was
measured by RT-qPCR corrected for b-actin mRNA. The values indicated
on the y-axis are fold changes in the RT-qPCR Units. n=4independent
experiments. (C) Empty vector (E) or pcDNA3-CBP-Flag was transfected
at the concentrations indicated (mg) and western blot analysis was done
to determine CBP protein over-expression.
doi:10.1371/journal.pone.0006766.g004
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one of their targets, H3K18 is not acetylated when iAs is present.
iAs Disrupts CARM1 but not GRIP1 Interaction with the
MMTV promoter
CARM1 is a protein methyltransferase (PRMT 4) that
specifically targets H3R17 for methylation [17] and acts
synergistically with p160 coactivators to enhance transcription
from steroid-regulated promoters including ER and GR [20,21].
Because H3R17 was less methylated in response to iAs, CARM1
could either be displaced from the MMTV promoter or be at the
promoter but not be enzymatically active. To distinguish between
these possibilities, cells were treated with Dex6iAs and ChIP
analysis was done with an antibody to CARM1. By 30 min of
treatment with Dex alone CARM1 was at the promoter but was
not when iAs was present (Fig. 5A). Western blot analysis of NEs
confirmed that CARM1 was available for binding and not
degraded after iAs treatment (Fig. 5B). Thus, iAs inhibits CARM1
interaction at the GR-activated MMTV promoter which can
account for the lack of H3R17me. ChIP assays also showed that
CARM1 interaction with the SGK promoter was inhibited by iAs,
similarly to the MMTV promoter (data not shown).
The p160 coactivator GRIP1 interacts with GR and CARM1
interacts with the promoter by binding to the C-terminal domain
of GRIP1 [33]. To determine if iAs affects GRIP1 interaction with
GR, cells were treated with Dex6iAs and ChIP assays were done
with antibody to GRIP1. There was no difference in the amount of
GRIP1 at NucB with iAS treatment (Fig. 5C). These data suggest
that iAs affects the CARM1/GRIP1 interaction but not the
GRIP1/GR interaction at the times tested. A sequential ChIP
experiment was done to test whether the CARM1/GRIP1
interaction was disrupted by iAs. Cells were treated with 5 nM
Dex68 mM iAs for 30 min and ChIP assays were done with
antibody to GRIP1 followed by antibody to CARM1. In the first
step, GRIP1 was found at NucB with Dex6iAs (Fig. 5D) as seen in
Fig. 5C. The GRIP1 immunoprecipitated material was then
incubated with antibody to CARM1 to determine whether
CARM1 was associated with GRIP1 at the promoter. The
CARM1/GRIP1 interaction was intact in the presence of Dex
alone but was not in the presence of Dex + iAs (Fig. 5D).
In vitro pull-down assays further tested CARM1 interaction with
the MMTV promoter in response to Dex + iAs (Fig. 5E–H). The
assay utilizes a short DNA fragment (Nucs A–C) of the MMTV
promoter assembled into a regularly spaced nucleosomal array
coupled to a magnetic bead (Fig. 5E). The in vitro MMTV template
was incubated with NE isolated from cells treated with Dex6iAs at
concentrations that inhibit transcription in these cells (Fig. 1B).
CARM1 bound to the promoter with Dex alone, but even at the
lowest concentration of iAs tested the amount of CARM1 bound
did not exceed that in NEs from untreated cells (zero) (Fig. 5F).
CARM1 seen in the untreated cells can be attributed to the low
level of background activation by GR resulting from a small
amount of GR in the nucleus before treatment (see EMSA-Fig. 2B-
Lane 2). NEs used in the pull-down reactions show an
approximately equal amount of CARM1 was present in all of
the NEs (Fig. 5G). These in vitro data confirm results from the ChIP
analysis (Fig. 5A) and support the conclusion that CARM1
interaction with the MMTV promoter is inhibited by iAs.
To determine whether the inhibition of CARM1 interaction
with NucB was a direct or an indirect effect of iAs on CARM1,
cells were treated with Dex alone and NE from the cells was
incubated with the in vitro MMTV DNA. iAs was added directly to
the in vitro reactions at concentrations equivalent to those found in
the nucleus after treatment of cells with 5 nM Dex + 8 mM iAs for
15 to 30 minutes as previously determined by Inductively Coupled
Plasma Mass Spectrometry (ICP-MS) analysis of NEs (data not
shown). There was no decrease in CARM1 bound at any
concentration of iAs added (Fig. 5H) as was seen when cells were
treated with iAs (labeled ‘‘Dex’’ and ‘‘D+As’’). These data suggest
that iAs does not have a direct effect on CARM1 but is acting
indirectly to disrupt the CARM1/GRIP1 interaction.
Over-expression of CARM1 restores iAs-inhibited
transcription
If the decrease in CARM1 promoter interaction is functionally
associated with the decrease in transcription due to iAs then over-
expression could overcome repression and restore transcription.
CARM1 was over-expressed and cells were treated with Dex6iAs.
CAT activity from the stably integrated MMTV-CAT reporter
was about 35% less in non-transfected (NT) cells treated with
Dex+iAs compared to Dex alone (Fig. 6A). In cells transfected with
0.5 mg CARM1, activity was restored in the iAs-treated cells to the
same levels as cells treated with 5 nM Dex alone. Because
CARM1 interacts with the promoter via GRIP1, GRIP1 was also
over-expressed to determine whether it could restore iAs-repressed
transcription. If over-expressed GRIP1 was able to restore
transcription it would raise the possibility that GRIP1 is also a
target for iAs. CAT activity in iAs-treated cells was slightly higher
than in similarly treated non-transfected (NT) cells, but was not
fully restored as with CARM1 over-expression. If 0.5 mg CARM1
was over-expressed with GRIP1, CAT activity was restored in iAs-
treated cells, but co-expression of 0.25 mg CARM1 (a concentra-
tion that does not restore CAT activity) with 0.1 or 2.5 mg GRIP1
did not restore CAT activity. Western blot analysis showed both
CARM1 and GRIP1 were over-expressed in transfected cells
(Fig. 6B).
Transcription from the SGK promoter was inhibited by iAs
treatment similarly to that at the MMTV promoter (Fig. 1D & E).
To determine if CARM1 or GRIP1 are functionally involved in
iAs-mediated transcriptional repression from the endogenous
SGK promoter, either CARM1 or GRIP1 were over-expressed
and SGK mRNA was quantified by qRT-PCR. As with CAT
activity, SGK mRNA expression was restored when CARM1 was
over-expressed (Fig. 6C). A somewhat higher level of transcription
was observed in the presence of iAs when GRIP1 was over-
expressed but not to the extent seen with CARM1 (Fig. 6D). These
data suggest that the decrease in transcription by iAs is functionally
related to the absence of CARM1 from the promoter because
over-expression restores GR-mediated activation. We cannot
discount that GRIP1 has a role in iAs-mediated transcriptional
repression from these data because there is less of an iAs effect
when it is over-expressed that is consistently seen in the over-
expression experiments.
Discussion
Inhibition of Transcription Initiation by iAs
Although we see little difference in initiated transcripts after 60
minutes of treatment with 5 nM Dex + 8 mM iAs compared to
Dex alone (Fig. 1C) we see a significant difference by 2 hours. This
suggests that iAs represses transcription through an effect on
initiation. The data from the REAA assays (Fig. 1D) in which iAs
inhibits GR-mediated chromatin remodeling lend more strength
to this hypothesis. The decrease in chromatin accessibility in the
presence of iAs suggests an effect on the chromatin remodeling
machinery. ATP-dependent chromatin remodeling complexes
found at steroid hormone receptor-regulated promoters include
the SWI/SNF-related BRG1 and brahma (BRM) ATPases. Both
Arsenic Inhibits CARM1
PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6766Figure 5. CARM1 but not GRIP1 interaction with the MMTV promoter is disrupted by iAs. (A) ChIP assay with an antibody to CARM1 of
1470.2 cells treated with 5 nM Dex68 mM iAs. qPCR was done with primers to NucB and values were corrected for Input DNA and expressed as a
ratio of treated to untreated (0) arbitrarily set to 1. n=4–6 independent experiments. (B) Western blot analysis of NEs treated as above incubated with
antibodies to CARM1 or b-actin. (C) ChIP assays and analysis as in (A) done with an antibody to GRIP1. Experiment shown is representative of 3
independent experiments. n=3 replicates. (D) Sequential ChIP analysis with antibodies to GRIP1 (first Ip) and CARM1 (second Ip). qPCR primers were
to NucB and values expressed as NucB/InPuts (%InPut). Experiment shown is representative of 4 independent experiments. n=3 replicates. (E)
CARM1 bound to the MMTV promoter decreases in the presence of iAs in an in vitro pull-down assay. Micrococcal nuclease digestion of an in vitro
assembled MMTV with Nucs A–C. DNA was visualized by agarose gel electrophoresis. Lane1=Molecular weight markers and Lane 2=MNase digested
MMTV assembled template. (F) In vitro assembled MMTV promoter (Nucs A–C) incubated with 60 mg NE from cells treated for 30 minutes with 5 nM
Dex6iAs from 0.5 to 8 mM. Proteins bound to the MMTV in vitro template were separated by SDS-PAGE followed by western blot analysis with
antibodies to CARM1 or to b-actin. A representative experiment repeated twice is shown. (G) Western blot analysis of NEs treated as in (F) incubated
with antibodies to CARM1 or b-actin. (H) NEs from cells treated with 5 nM Dex incubated with the in vitro template and exogenously added iAs from
0.1 to 1.5 mM. Western blot of MMTV-associated proteins with antibody to CARM1. Lane 0=NE from untreated cells, Lane ‘‘Dex’’=NE from 5 nM Dex
treated cells and Lane ‘‘D+As’’ is NE from cells treated with 5 nM Dex+8 mM iAs. Below is the same blot incubated with antibodies to histone H3.
Representative of an experiment repeated twice.
doi:10.1371/journal.pone.0006766.g005
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promoters [34–37]. Interestingly, BRG1 and CARM1 have been
co-purified in a complex, Nucleosomal Methylation Activator
Complex (NUMAC) on an ER-target gene where they physically
interact with each other [38]. Furthermore, binding of BRG1 to
the late myogenic gene promoters is facilitated by CARM1. If
CARM1 is not present, BRG1 is not found at these promoters
[39]. Data presented here show that at the MMTV promoter
there is decreased chromatin remodeling in the presence of iAs
and CARM1 is not present at the promoter. These data suggest
that BRG1 or another ATP-dependent chromatin remodeling
factor may not be associated with the promoter. How iAs inhibits
chromatin remodeling at the MMTV promoter is currently under
investigation.
Coactivator interactions
GRIP1 was found at NucB on the MMTV promoter following
Dex + iAs treatment but CARM1 was not which suggested that
iAs may inhibit transcription by disrupting the CARM1-GRIP1
interaction (Fig. 5C). Furthermore, in a sequential ChIP assay in
which GRIP1 was first immunoprecipitated followed by CARM1,
the GRIP1-CARM1 interaction was disrupted by iAs. Addition-
ally, over-expression of CARM1 restored iAs-repressed transcrip-
tion, Together these data strongly suggest that CARM1 is a likely
iAs target in the cell. GRIP1 was at the promoter in cells treated
with iAs, and over-expression was able to partially restore
transcription. Thus we cannot eliminate the possibility that
GRIP1 is a target for iAs. A problem we encountered in the
GRIP1 over-expression experiments was that we could achieve
only small increases in GRIP1 protein by over-expression despite
seeing significant increases in GRIP1 mRNA (data not shown). All
three of the p160 coactivator proteins are regulated by
phosphorylation-dependent ubiquitin-proteasomal pathways [40–
43] which is likely why there is a limited amount of GRIP1 protein
over-expression relative to the increase in mRNA in these cells.
Because GRIP1 is at the promoter in the presence of iAs and it
interacts with the MMTV promoter via GR [44], the GR-GRIP1
interaction must be intact. An effect of GRIP1 over-expression on
transcription would also depend on the stability of the GR-GRIP1
interaction. If the interaction is very stable and there is little
turnover, then GRIP1 over-expression may not be effective in
replacing the GRIP1 already there. This could account for the
very small increase in transcription when GRIP1 is over-expressed
and leaves open the possibility that GRIP1 is an iAs target.
The GRIP1-CARM1 interaction domain on either protein may
be a target for iAs resulting in CARM1 dissociation from GRIP1,
or alternatively, another protein that stabilizes the CARM1-
GRIP1 interaction could be an iAs target. The first possibility
would be consistent with iAs mediated changes in interaction
domain PTMs that affect CARM1-GRIP1 protein-protein
Figure 6. Over-expression of CARM1 restores iAs-mediated
transcriptional repression. (A) Cells were transfected with pSG5-HA-
CARM1, pSG5-GRIP1/FL or a combination of the two expression
plasmids at indicated concentrations and treated with 5 nM Dex68 mM
iAs for 24 h. CAT activity was measured and expressed as percent
conversion from unacetylated to acetylated chloramphenicol. Repre-
sentative of an experiment repeated 3 times n=3 replicate points. (B)
Western blot analysis of proteins from cells transfected with 0.5 mgo f
pSG5-HA-CARM1 or pSG5-GRIP1/FL plasmid or non-transfected cells
(NT), incubated with antibodies to CARM1, GRIP1 and b-actin. The HA-
tagged CARM1 migrates slightly higher in the gel than endogenous
CARM1. (C) Cells transfected with pSG5-HA-CARM1 at the indicated
concentrations or pSG5-HA-EMPTY at 1.5 mg and treated for 2 hours
with 5 nM Dex68 mM iAs. SGK mRNA was measured by RT-qPCR
corrected for actin mRNA. The values indicated on the y-axis are RT-
qPCR Units. Experimental points are in triplicate and the experiment
was repeated twice. (D) pSG5-GRIP1/FL or Empty vector was over-
expressed in cells at the concentrations indicated and SGK mRNA was
measured by RT-qPCR and analyzed as in (C).
doi:10.1371/journal.pone.0006766.g006
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C-terminal AD2 domain of GRIP1/SRC2 via CARM1s central
domain [45] and PTMs on the related p160 coactivator SRC3/
AIB1/p/CIP, including phosphorylation and methylation medi-
ated by cell signaling pathways, affect coactivator complex
assembly and stability on ERs [46–48]. Interestingly, there are
three predicted sites for p38MAPK-mediated phosphorylation in
the AD2 domain of GRIP1 where CARM1 binds [49]. iAs has
stimulatory and inhibitory affects on multiple signaling pathways
including p38MAPK [50] as well as extracellular signal-regulated
kinases (ERK1/2), c-Jun terminal and stress activated kinases
JNK/SAPKs [51], and mitogen-activated protein kinases
(MAPKs), (MSK1)[52]. These pathways have the potential to
post-translationally modify either CARM1 or GRIP1 [53,54]. If
the interaction between the two proteins is destabilized rather than
completely inhibited by iAs, an increase in the concentration of
either protein could change the equilibrium characteristics in the
nucleus and potentially drive enough of an interaction to restore
transcription. The experiments in which transcription increased in
parallel with CARM1 over-expression support destabilization of
the CARM1-GRIP1 interaction by iAs (Fig. 6A & C). The data
also support an indirect effect of iAs on CARM1 (Fig. 5H) which
would be consistent with inappropriate PTMs on either CARM1
or GRIP1 mediated by the disruption of a cell signaling pathway.
It is also possible that another protein that stabilizes the CARM1-
GRIP1 interaction is an iAs target. For example TIF1a/Trim24
forms a complex with CARM1 and GRIP1 and its role may be in
stabilizing the CARM1-GRIP1 interaction [55] making TIF1a a
candidate iAs target in these cells.
The stability of CARM1 at promoters may also be affected by
acetylation of H3K18 and H3K23 [19]. The significant decrease
in H3K18ac in response to iAs exposure by 15–30 minutes
(Fig. 3A) is likely due to the inactivation of a promoter-bound
acetyltransferase such as CBP or p300, both of which target
H3K18 for acetylation [19,27]. CBP associates with the MMTV
promoter equally well in cells treated with Dex6iAs (Fig. 4A) as
does p300 (data not shown) which makes inactivation of histone
acetyltransferase (HAT) activity a likely possibility. Thus, if the
stability of CARM1 at the promoter is dependent on H3K18ac,
the inactivation of CBP HAT activity may be a critical event in
iAs-mediated inactivation of transcription and would almost
certainly affect other aspects of the activation process [56].
Ongoing studies will determine whether iAs inhibits HAT activity
of CBP and post-translational modifications on CBP or p300 that
can influence HAT activity to begin to determine their role in
transcriptional repression by iAs.
iAs-mediated Inhibition of Histone Modification
The apparent level of H3K18ac and H3R17me in response to
iAs in these experiments was below basal levels (Fig. 3). It is
possible that a demethylase (H3R17) or a histone deacetylase
(H3K18) is inappropriately associated with the promoter. Notably,
nickel and chromium, two genotoxic metals, repress transcription
rapidly and do so partially through mechanisms that affect histone
modification [57–59]. However, there are multiple copies of
MMTV-CAT stably integrated in the cell line used here and there
is basal transcription from the MMTV promoter before the cells
are treated. This would be associated with some H3K18
acetylation and H3R17 methylation. The small increase in
H3K18ac and H3R17me compared to basal levels following
treatment with Dex (Fig. 3) is likely because basal levels of
modification are high which minimizes the amount of detectable
increase with Dex treatment. Likewise, when iAs is present and
histone PTMs are inhibited, basal transcription would also be
inhibited. This is apparent in the REAA assay shown in Fig. 1D
where chromatin remodeling is inhibited to below basal levels by
iAs. Furthermore, it has been demonstrated that in a related cell
line there is a population of open (active) chromatin templates in
the basal state and some inactive or closed chromatin templates in
the activated state [60]. Thus, we think it less likely that a
deacetylase is responsible for decreased H3K18ac due to iAs than
to inhibition of an acetylase activity, for example by CBP or p300.
A mechanism common to iAs-mediated transcriptional
inhibition at other promoters?
To date the mechanisms that underlie iAs-mediated disruption
of transcription by steroid hormone receptors have not been
characterized, although it is well documented that transcription by
these highly related receptors is disrupted by exposure to iAs in the
low micromolar range [7–10]. Because iAs can bind to vicinal
thiols which are found in the steroid binding domain and the DNA
binding domain of steroid hormone receptors [61], two possible
hypotheses are that iAs might inhibit transcription by interfering
with either steroid binding to receptor or receptor binding to
DNA. In fact Simons et al [62] showed that in an in vitro system
7 mM iAs was effective in inhibiting Dex binding to GR. However,
this concentration of iAs is not an achievable intracellular
concentration because it would be toxic and result in cell death.
In our analyses by ICP-MS of intracellular As
+3 we found that
treatment of cells with 8 mM iAs for 15 minutes to 1 hour, resulted
in only 0.1 to 1.5 mM intranuclear As
+3 with a correlation between
the length of time of treatment and the amount of As
+3 detected
(data not shown). Note that these are the concentrations used in
the in vitro system to determine whether iAs is acting directly or
indirectly on proteins at the promoter (Fig. 5H). Treatment of
1470.2 cells with higher iAs concentrations than 8 mM induces a
stress response and results in cell death (data not shown). Others
have shown that GR does in fact translocate from the cytoplasm to
the nucleus in the presence of iAs at similar concentrations to those
used in this study [7]. This transition is ligand dependent and it is
shown here that GR binds to a GRE equally well in cells that have
been treated with iAs at levels that inhibit transcription (Fig. 2).
Thus it appears that netiher iAs-mediated inhibition of steroid
hormone binding to GR or GR binding to the promoter are likely
mechanisms underlying inhibition of transcription by iAs.
Because both CARM1 and one of the p160 coactivators (SRC1,
GRIP1/SRC2/TIF2, or SRC3/AIB1/p/CIP/TRAM) are essen-
tial to transcriptional regulation at all steroid hormone receptor-
regulated promoters, identification of CARM1 and GRIP1 as
players in iAs-mediated transcriptional inhibition raises the
possibility that iAs may repress transcription by other steroid
hormone receptors similarly. In support of this, we have found that
iAs-mediated inhibition of an estrogen-responsive promoter in
MCF7 breast cancer cells is functionally related to iAs effects on
CARM1 and on SRC3/AIB1 a GRIP1 homologue that interacts
with ERs (manuscript in preparation). While this manuscript was
in preparation it was reported that TIF2, the human homologue of
GRIP1/SRC2, does not bind to an AR-regulated promoter in
LNCaP cells 24 hours after treatment with arsenic trioxide
(As2O3/ATO) and an androgen [63]. It was also shown that AR
was no longer at the promoter 24 hours after ATO treatment
however, and p160 coactivators interact with hormone-responsive
promoters via interaction with steroid receptors so TIF2 would not
be expected to be there. No direct evidence to support iAs-
mediated disruption of the AR/TIF2 interaction is shown. Our
data shows that iAs inhibits CARM1 but not GRIP1/SRC2
interaction with the GR-activated MMTV promoter as early as 30
minutes following treatment with Dex and iAs in the form of
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coactivator interaction than NaAsO2 but this is unlikely since both
forms are sources of trivalent inorganic arsenic (As
3+). It is also
certain that after 24 hours of treatment the promoter-associated
proteins would be very different than at 30 min after treatment.
Because of the significant differences in the experimental
approaches used it is difficult to determine from these data
whether the dynamics of GRIP1/TIF2 interaction are the same or
different in response to iAs and steroid hormone at GR and AR-
regulated promoters.
CARM1 and p160 coactivator family members are also part of
the transcription complex with some non-steroid-regulated
transcription factors including p53 [64]. Thus the disruption of
CARM1 promoter interaction associated with exposure to low
levels of iAs could potentially extend beyond steroid hormone-
regulated gene expression. This would increase the potential for
deleterious physiological effects on virtually every metabolic
system by iAs and would further explain how iAs exposure can
be associated with the multiplicity of diseases that it is.
Long term exposure to iAs is associated with many different
diseases but is also used as a cancer therapeutic, primarily in the
form of ATO. Interestingly, ATO inhibits the interaction of the
corepressor SMRT with the fusion protein promyelocytic
leukemia-retinoic acid receptor-a (PML-RARa) contributing to
possible mechanisms in iAs-mediated remission in acute promy-
elocytic leukemia (APL) [65,66]. AIB1/SRC3, is an oncogene,
amplified in breast, prostate, pancreatic, and other cancers [67]
and CARM1 is over-expressed in grade-3 breast cancer tumors
[68]. CARM1 and p160 family members have been suggested as
potential targets in cancer therapy. We suggest that some of the
known therapeutic effects of iAs may be related to an effect on the
CARM1-GRIP1 interaction demonstrated here. iAs inhibition of
the GRIP1-CARM1 interaction could be beneficial if these
proteins are inappropriately over-expressed as in some cancers,
but iAs could also lead to disease if it disrupts the normal function
of GRIP1-CARM1 interaction. Data presented here provide
strong evidence that iAs disruption of transcriptional coactivator
function is a key piece in iAs-mediated repression of steroid
hormone-regulated gene transcription. It will be important to
further characterize the mechanism of iAs-mediated disruption of
the CARM1-GRIP1 interaction and to identify how other proteins
such as CBP/p300 are involved in iAs-mediated transcriptional
repression to more fully understand how iAs can be both
detrimental to health and also be an effective therapeutic.
Materials and Methods
Cell Culture
The 1470.2 cell line derived from the mouse adenocarcinoma
parent line, C127i, constitutively expresses GR and has multiple
copies of stably integrated MMTV-chloramphenicol acetyl
transferase (MMTV-CAT) [69]. Cells were grown in DMEM
(Gibco) with either 10% calf serum (CS), or charcoal stripped 1%
CS for 16–24 h prior to treatment with Dex (Steraloids, Newport,
RI)6sodium arsenite (NaAsO2) (ScienceLab.com).
Chromatin Immunoprecipitation (ChIP) Assays
Cells were cross-linked with 1.5 mM Ethylene Glycol-bis
(Succinimidylsuccinate) (EGS) (Pierce, Rockford, IL) at 25uC for
25 min followed by 1.0% formaldehyde at 25uC for 10 min (GR,
CARM1, GRIP1) or with formaldehyde only (Histone PTMs).
Nuclei were isolated, and DNA digested to predominantly
monosomes with micrococcal nuclease (0.0375 U/mg nucleic acid)
(Roche Applied Science, Indianapolis, IN) 37uC for 6 min. ChIP
was as described by the Upstate Biotechnology ChIP protocol
(Upstate Millipore.com). Incubation with specific antibody or non-
immune IgG was overnight at 4uC, protein A sepharose or
magnetically coupled Protein G beads (Dynal/InVitrogen) were
used to isolate immune complexes. In Sequential ChIPs antibody-
antigen complexes from the first Ip were eluted by incubation in
10 mM DTT for 30 min at 37uC. Samples were diluted in 20
volumes 1% triton X-100, 2 mMEDTA, 150 mM NaCl, 20 mM
Tris 8.0 and antibody added. Wash buffers were High salt
(500 mM NaCl, 50 mM Tris 8.0, 1%NP-40, 0.1% SDS, 1 mM
EDTA), Low Salt (150 mM NaCl, and as above with the addition
of 0.5% Deoxycholate), LiCl wash (250 mM LiCl, and as above).
Elution from beads was in 50 mM NaCl, 10 mM Tris 7.5,
5 mMEDTA with 0.5% or 1.2% SDS for 15minutes at room
temp. DNA was purified with MinElute columns (Qiagen) and
quantified by fluorimetry with PicoGreen (Molecular Probes,
Eugene, OR) on a Synergy HT plate reader (Biotek, Winoos-
ki,VT) or by NanoDrop spectrophotometer (ThermoScientific,
Fisher). Non-immune rabbit IgG was used to determine non-
specific antibody interactions and was subtracted from specific
interactions. Primers to an unrelated genomic region, ribosomal
protein L30 (RPL30) (Cell Signaling Technology, Danvers,MA) or
to 5S ribosomal DNA were used to determine that the changes
seen were specific to the promoter.
PCR Protocols
ChIP DNA was analyzed by quantitative real-time (qPCR) with
a TaqMan MGB Probe with a 6-FAM reporter and primers to
MMTV Nuc B (Table S1) (Applied Biosystems, Foster City, CA)
on a MJ Research Chromo4 RealTime PCR Detector DNA
Engine (Bio-Rad, Hercules, CA). qPCR values were quantified by
Absolute Standard Curve Method using plasmid pM25 (MMTV
promoter) [69], corrected for Input DNA (NucB/Corresponding
Input Value) and expressed as a ratio relative to untreated cells
(arbitrarily set to 1). Other mRNAs were quantified using
SyberGreen (iQ SyberGreen SuperMix, BioRad) and normalized
to b-Actin mRNA by the Comparative C(t) method [70] after
cDNA was made, referred to as reverse transcibed quantitative
PCR (qRT-PCR). cDNA for PCR was synthesized with MuLV
reverse transcriptase (NEB, Ipswich,MA), and Random hexamers
(Roche, Nutley,NJ). See Table S1 for Primers and probes used in
PCR.
Antibodies
See Table S2-Antibodies
Nuclear Extracts (NEs)
Mini-Dignam NEs were made [71]. Cells were lysed in Buffer A
(10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
DTT), nuclei were isolated/extracted in Buffer C (20 mM
HEPES, pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT) and dialysis was
for 2 hr against Buffer D (20 mM HEPES, 7.9, 20% glycerol,
0.1 M KCl, 0.5 mM PMSF, 0.5 mM DTT, 5 mM MgCl2).
Protein was measured by Bradford assay (BioRad, Hercules,CA).
Electromobility shift assays (EMSA)
EMSAs included 20 mg of NE in Buffer D with 30–60 fmol of
[
32P]-end-labeled wtGRE, 59-GATCCGGTacaATCtgtTCTA-39
[25], and 0.2 mg poly(dI-dC).poly(dI-dC) (Roche, Nutley,NJ) in
20 ml reactions separated on 5% acrylamide/0.5X Tris/Borate/
EDTA gels at 4uC. Imaging was by PhosphorImager analysis
(Molecular Dynamics) and quantification by ImageQuant software.
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Proteins were separated on 10% polyacrylamide gels Pierce
(Rockford, IL) or NuPAGE Novex BisTris 4–20% gradient gels
(Invitrogen) in recommended buffers, transferred to Immobilon-P
PVDF membrane (Millipore) and visualized by HRP-based
chemiluminescence imaged on film or on an Alpha Innotek
FluoroChem 8900 (San Leandro, CA).
Nuclear Run-ons
Isolated nuclei (0.5 mg) were resuspended in 100 ml (10 mM
Tris pH 8.0, 5 mM MgCl2, 40% glycerol, 2.5 mM DTT). One
hundred microliters of 2x reaction mix (10 mM Tris 8.0, 5 mM
MgCl2, 200 mM KCl, 200 U/ml RNasin, 1 mMCTP,1 mM
GTP, 2 mM ATP, 2 mM UTP, 5 mM DTT) was added with
120 mCi/200 ml reaction [
32P]-UTP (3000 Ci/mmol) (ICN Phar-
maceuticals, Costa Mesa, CA). and incubated for 45 min 30uC.
RNA was extracted with TRI Reagent LS (Molecular Research
Center, Cincinnati, OH) and equal counts were added to
nitrocellulose filters (Schleicher and Schuell, Keene, NH) previ-
ously blotted with PCR-amplified CAT reporter DNA (1 mgo f
1 kB coding region), an equal amount of pUC18 DNA for
background subtraction, and 5 s DNA for normalization.
Hybridization was at 42uC in 50% formamide, 5x SSPE, 3x
Denhardt’s, 100 mg/ml yeast tRNA and 0.5% SDS for 12–16 h.
Visualization/Quantification was on a Storm Typhoon Phosphor-
Imager and ImageQuant analysis (Molecular Dynamics, Sunny-
vale, CA).
Restriction Enzyme Accessibility Assay (REAA)
Nuclei were harvested from treated cells and a portion
quantified after proteinase K digestion (InVitrogen). 50 mg nuclei
were digested with 10 U/mg SacI, New England Biolabs, for 15
minutes at 37uCi n5 0ml of 50 mM NaCl, 50 mM Tris pH 8.0,
1 mM MgCl2,1 m Mb-mercaptoethanol, 2.5% glycerol. The
reaction was terminated with 5 vol. 10 mM Tris (pH 7.5), 10 mM
EDTA, 0.5% SDS, 100 mg/ml proteinase K, and digested
overnight at 37uC to extract genomic DNA. DNA was prepared
for qPCR by Min-Elute columns (Qiagen) and quantified by
NanoDrop spectrophotometer (ThermoScientific, Fisher). qPCR
was with 15–30 ng total DNA and primers that flank the SacI site
in NucB (see Table SI). A PCR product indicated chromatin
inaccessibility because the SacI site was not accessible. Quantifi-
cation of PCR product was by the Comparative C(t) method with
normalization to b-Actin. Percent Accessibility=(12 (Treated/
Untreated)) x100.
Magnetic Bead DNA
A 1.8 kb Sph1/Nco1 fragment of the MMTV LTR from the
pGEM3ZFM-LTRCAT plasmid that includes Nucs A-F of the
MMTV promoter, was biotinylated (20 ug DNA fragment, 1x
Klenow Buffer, 1 mM MgCl2,5 0mM each dTTP aS, dGTP aS,
dCTP aS (Axxora, San Diego, CA), 18 mM Biotin-14-dATP
(Invitrogen Carlsbad, California), 10 U Klenow (Invitrogen,
Carlsbad, California) at 25uC for 15 min and attached to
streptavidin-coated magnetic beads using the Dynabead Kilobase
Binder Kit (Dynal Biotech, Lake Success, NY) in 200 ml Kit
binding buffer as described by Fletcher et al [72]. Digestion with
Ple1 left Nucs A–C attached to the bead.
Chromatin Assembly
Bead DNA (Nucs A–C) was assembled with HeLa core histones
using Active Motif’s (Carlsbad CA) Chromatin ATP-dependent
Assembly Kit that utilizes purified recombinant human chromatin
assembly complex ACF, and histone chaperone NAP-1 with
modifications. Post assembly, 36200 ml washes were done in
Wash 1: Storage Buffer (SB)(10 mM HEPES (pH 7.8),
10 mMKCl, 1.5 mMMgCl2, 0.5 mM EDTA, 10% glycerol
10 mM b-glycerophosphate, 0.1% NP-40, 1 mg/ml acetylated
BSA (Sigma), 0.5% Sarkosyl). Wash 2: SB with 200 mM KCl.
Wash 3: SB with 2 mg/ml BSA. Washes 1 and 3 were at 25uC and
wash 2 at 4uC. Assembled DNA was stored in SB with protease
inhibitor cocktail (Calbiochem, San Diego, CA) no more than 2
days at 4uC before use.
Pull-Down Assay
Chromatin assembled bead DNA was washed twice in Pull-
Down buffer (20 mM Hepes [pH 7.3], 50 mM NaCl, 10%
Glycerol, 0.05 mM EDTA, 5 mM MgCl2, 0.1% NP-40, 1 mM
DTT, 0.5 mM PMSF, 1:100 protease inhibitor cocktail (Calbio-
chem, San Diego, CA) and resuspended at 0.01 ug/ul. Reaction
components were 31 ul Pull-down buffer, 2 ul 50 mg/ml
acetylated BSA (Sigma-Aldrich, St. Louis, MO), 0.5 ul poly
(dI:dC). poly (dI:dC) (Pharmacia) 1.0 ug/ul), 60 ug Nuclear
Extract, 0.05 ug bead DNA, Buffer D to 50 ul on ice in a 96
well round-bottom polypropylene plate (Costar). After incubation
at 30uC for 15 min immobilized bead DNA was magnetically
immobilized (Dynal Inc., Lake Success, NY) to remove reaction
mix and 2X 50 ul washes in cold Pull-down buffer. Bead DNA-
bound proteins were separated on denaturing 4–20% Tris-Glycine
gels (Invitrogen Carlsbad, California), followed by Western Blot
analysis.
Plasmid Transfections
Over-expression plasmids were pSG5-HA-CARM1 and pSG5-
GRIP1/FL [33,44] or pcDNA3-CBP-Flag [73,74]. Lipofectamine
Plus (Invitrogen, Carlsbad, CA) was used as directed in 12-well or
6-well cluster plates. Cells recovered for 24 h and medium was
replaced with 1% stripped serum (HyClone) in DMEM. 24–48 h
post-transfection cells were treated with Dex6iAs for indicated
times, were harvested and resuspended in 0.25 M Tris (pH 7.5) for
CAT and Bradford protein assays (Bio-Rad, Hercules, CA) or
lysed in Cell Lysis Buffer (20 mM Tris 7.5, 100 mM NaCl, 0.5%
NP-40, 0.5 mM EDTA, Protease inhibitors (Roche, Nutley, NJ))
for western blot analysis. Alternatively, RNA was isolated with
RNeasy columns (Qiagen) and cDNA prepared for qRT-PCR.
Chloramphenicol Acetyltransferase (CAT) Assays
Five micrograms protein was incubated for 30 min at 37uC with
[
14C]-chloramphenicol (ICN, Costa Mesa, CA) and 4 mM acetyl
CoA (Sigma-Aldrich, Nutley, NJ), extracted with ethyl acetate and
CAT activity was measured by thin layer chromatography.
Acetylated products were visualized on a Molecular Dynamics
PhosphorImager and analyzed with ImageQuant (GE Healthcare
Life Sciences, Piscataway, NJ). CAT activity was expressed as
percent conversion (acetylated chloramphenicol/total chloram-
phenicol).
Statistical Analyses
Data are expressed as means and SEM. Statistical significance
was determined by two-tailed t-test assuming equal variances.
Supporting Information
Table S1 PCR Primer sequences
Found at: doi:10.1371/journal.pone.0006766.s001 (0.04 MB
DOC)
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Found at: doi:10.1371/journal.pone.0006766.s002 (0.00 MB
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